Mayne Pharma outsources its clinical trials to reputable Contract Research Organisations (CROs). Mayne Pharma is ethically and legally obligated to ensure the safety, quality and efficacy of its products. Ethics approval is obtained (as required) for all applicable clinical trials.
Whilst the use of animals remains necessary in the development and testing of some of our novel products, Mayne Pharma is committed to ensuring the highest standards of animal welfare. In every clinical trial protocol, we have specific language with respect to animal welfare, applicable laws and meeting international standards.
Mayne Pharma adheres to the Three Rs, being the Replacement, Reduction and Refinement of animals in Research.
- Replacement: Mayne Pharma is a strong advocate for the development of new and valid methods that will replace the need for laboratory animals in medical and scientific research, education and testing, and will seek out such alternatives wherever possible and viable going forward
- Reduction: Mayne Pharma is committed to reducing the numbers of animals involved in any of our operations to the lowest unavoidable minimum, where the use of animals is required by legal or ethical obligations
- Refinement: Mayne Pharma supports and requires of our CROs the refinement of experimental or research procedures to minimise, and where possible, remove, any animal suffering